US2009274717A1PendingUtilityA1

Genes and proteins, and their use

57
Assignee: EMERGENT PRODUCT DEV UK LTDPriority: Dec 22, 1998Filed: Aug 17, 2007Published: Nov 5, 2009
Est. expiryDec 22, 2018(expired)· nominal 20-yr term from priority
Inventors:Martin John Glenton HughesJoseph David SantangeloJonathan Douglas LaneRobert FeldmanJoanne Christine MooreRichard James DobsonPaul EverestGordon DouganRebecca Kerry Wilson
A61P 31/04A61P 27/02A61P 19/02A61P 13/02A61P 19/00C07K 14/315A61K 39/092A61K 48/00G01N 33/56944A61K 39/00C12N 15/11Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
     
     
         20 . An isolated polypeptide comprising an amino acid sequence which has greater than 95% similarity to SEQ ID NO: 23. 
     
     
         21 . The polypeptide of  claim 20 , wherein said amino acid sequence comprises SEQ ID NO: 23. 
     
     
         22 . The polypeptide of  claim 21 , wherein said amino acid sequence is encoded by SEQ ID NO: 22 
     
     
         23 . The polypeptide of  claim 20 , further comprising a heterologous polypeptide. 
     
     
         24 . A composition comprising the polypeptide of  claim 20  and a carrier. 
     
     
         25 . The composition of  claim 20 , further comprising an adjuvant. 
     
     
         26 . The composition of  claim 25 , wherein said adjuvant is alum. 
     
     
         27 . The composition of  claim 20 , which induces an immune response against said polypeptide when administered in an animal. 
     
     
         28 . The composition of  claim 27 , wherein said immune response is a humoral immune response. 
     
     
         29 . The composition of  claim 27 , wherein said immune response is a cell mediated immune response.

Join the waitlist — get patent alerts

Track US2009274717A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.